奥司他韦、帕拉米韦和法匹拉韦三种抗病毒药物体外抑制新型重组禽流感H7N9病毒感染的研究

Q2 Pharmacology, Toxicology and Pharmaceutics

Antiviral Chemistry and Chemotherapy Pub Date : 2014-12-16 DOI:10.3851/IMP2672

Rui-Yuan Cao, Jun-Hai Xiao, Bin Cao, Song Li, Yohichi Kumaki, Wu Zhong

{"title":"奥司他韦、帕拉米韦和法匹拉韦三种抗病毒药物体外抑制新型重组禽流感H7N9病毒感染的研究","authors":"Rui-Yuan Cao, Jun-Hai Xiao, Bin Cao, Song Li, Yohichi Kumaki, Wu Zhong","doi":"10.3851/IMP2672","DOIUrl":null,"url":null,"abstract":"Background: A novel reassortant avian-origin influenza A (H7N9) virus was isolated from respiratory specimens obtained from three patients and was identified as H7N9 in China. Antiviral agents are required to treat patients with avian influenza H7N9 virus infection.Methods: In this study, we assessed the antiviral potential of oseltamivir, peramivir, favipiravir (T-705), amantadine and rimantadine against novel reassortant avian-origin influenza H7N9 virus in vitro.Results: All three avian influenza H7N9 virus strains were sensitive to oseltamivir, peramivir and favipiravir (T-705), but resistant to amantadine and rimantadine.Conclusions: Our data show a pattern of antiviral sensitivity for this novel H7N9 strain of influenza that suggests the compounds oseltamivir, peramivir and favipiravir should be useful for therapy.","PeriodicalId":7960,"journal":{"name":"Antiviral Chemistry and Chemotherapy","volume":"23 6","pages":"237-40"},"PeriodicalIF":0.0000,"publicationDate":"2014-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3851/IMP2672","citationCount":"24","resultStr":"{\"title\":\"Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir.\",\"authors\":\"Rui-Yuan Cao, Jun-Hai Xiao, Bin Cao, Song Li, Yohichi Kumaki, Wu Zhong\",\"doi\":\"10.3851/IMP2672\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: A novel reassortant avian-origin influenza A (H7N9) virus was isolated from respiratory specimens obtained from three patients and was identified as H7N9 in China. Antiviral agents are required to treat patients with avian influenza H7N9 virus infection.Methods: In this study, we assessed the antiviral potential of oseltamivir, peramivir, favipiravir (T-705), amantadine and rimantadine against novel reassortant avian-origin influenza H7N9 virus in vitro.Results: All three avian influenza H7N9 virus strains were sensitive to oseltamivir, peramivir and favipiravir (T-705), but resistant to amantadine and rimantadine.Conclusions: Our data show a pattern of antiviral sensitivity for this novel H7N9 strain of influenza that suggests the compounds oseltamivir, peramivir and favipiravir should be useful for therapy.\",\"PeriodicalId\":7960,\"journal\":{\"name\":\"Antiviral Chemistry and Chemotherapy\",\"volume\":\"23 6\",\"pages\":\"237-40\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-12-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3851/IMP2672\",\"citationCount\":\"24\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Antiviral Chemistry and Chemotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3851/IMP2672\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Antiviral Chemistry and Chemotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3851/IMP2672","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 24

摘要

背景:从3例患者呼吸道标本中分离到一种新型重组禽源性甲型H7N9病毒，经鉴定为H7N9。需要抗病毒药物治疗H7N9禽流感病毒感染患者。方法:在体外研究奥司他韦、帕拉米韦、法匹拉韦(T-705)、金刚烷胺和金刚乙胺对新型重组禽流感H7N9病毒的抗病毒作用。结果:3株H7N9禽流感毒株均对奥司他韦、帕拉米韦和法匹拉韦(T-705)敏感，对金刚烷胺和金刚乙胺耐药。结论:我们的数据显示了这种新型H7N9流感病毒的抗病毒敏感性模式，这表明化合物奥司他韦、帕拉米韦和法匹拉韦应该是有效的治疗方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir.

Background: A novel reassortant avian-origin influenza A (H7N9) virus was isolated from respiratory specimens obtained from three patients and was identified as H7N9 in China. Antiviral agents are required to treat patients with avian influenza H7N9 virus infection.

Methods: In this study, we assessed the antiviral potential of oseltamivir, peramivir, favipiravir (T-705), amantadine and rimantadine against novel reassortant avian-origin influenza H7N9 virus in vitro.

Results: All three avian influenza H7N9 virus strains were sensitive to oseltamivir, peramivir and favipiravir (T-705), but resistant to amantadine and rimantadine.

Conclusions: Our data show a pattern of antiviral sensitivity for this novel H7N9 strain of influenza that suggests the compounds oseltamivir, peramivir and favipiravir should be useful for therapy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Antiviral Chemistry and Chemotherapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

5.20

自引率

0.00%

发文量

审稿时长

15 weeks

期刊介绍： Antiviral Chemistry & Chemotherapy publishes the results of original research concerned with the biochemistry, mode of action, chemistry, pharmacology and virology of antiviral compounds. Manuscripts dealing with molecular biology, animal models and vaccines are welcome. The journal also publishes reviews, pointers, short communications and correspondence.